Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2022-05-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 15
- Registration Number
- NCT03757351
- Locations
- 🇳🇱
CHDR, Leiden, South Holland, Netherlands
🇺🇸Bioclinica, Orlando, Florida, United States
🇺🇸PRA Health Sciences, Salt Lake City, Utah, United States
Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 25
- Registration Number
- NCT03733717
- Locations
- 🇨🇳
Investigational Site Number 1560003, Beijing, China
🇨🇳Investigational Site Number 1560001, Tianjin, China
🇨🇳Investigational Site Number 1560002, Nanjing, China
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 370
- Registration Number
- NCT03713684
- Locations
- 🇺🇸
Investigational Site Number 8400005, Glendale, Arizona, United States
🇰🇷Investigational Site Number 4100009, Busan, Korea, Republic of
🇰🇷Investigational Site Number 4100014, Jeonju, Korea, Republic of
Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.
- First Posted Date
- 2018-10-12
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 4589
- Registration Number
- NCT03703869
- Locations
- 🇨🇴
Investigational Site Number 1700005, Cali, Colombia
🇨🇴Investigational Site Number 1700010, Bogota, Colombia
🇨🇴Investigational Site Number 1700009, Cali, Colombia
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
- Conditions
- Dermatitis Atopic
- Interventions
- Other: Standard of care
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1856
- Registration Number
- NCT03687359
- Locations
- 🇺🇸
C Squared Research Center- Site Number : 8400068, Birmingham, Alabama, United States
🇺🇸Cahaba Dermatology & Skin Health Center- Site Number : 8400046, Birmingham, Alabama, United States
🇺🇸C2 Research Center, LLC- Site Number : 8400071, Montgomery, Alabama, United States
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 908
- Registration Number
- NCT03684642
- Locations
- 🇺🇸
Investigational Site Number 8400009, Los Angeles, California, United States
🇺🇸Investigational Site Number 8400059, Skokie, Illinois, United States
🇺🇸Investigational Site Number 8400061, Boston, Massachusetts, United States
Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female Subjects
- First Posted Date
- 2018-09-21
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 5
- Registration Number
- NCT03681158
- Locations
- 🇬🇧
Investigational site number, Nottingham, United Kingdom
Study Evaluating the Efficacy and Safety of Fexofenadine in Subjects Suffering From Seasonal Allergic Rhinitis in Presence of Pollutants
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 240
- Registration Number
- NCT03664882
- Locations
- 🇨🇦
Investigational Site Number, Canada, Canada
Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria
- Conditions
- Plasmodium Falciparum Infection
- Interventions
- Drug: Ferroquine (SSR97193)
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 140
- Registration Number
- NCT03660839
- Locations
- 🇧🇯
Investigational Site Number 2040001, Cotonou, Benin
🇧🇫Investigational Site Number 8540002, Banfora, Burkina Faso
🇬🇦Investigational Site Number 2660002, Lambarene, Gabon
Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 107
- Registration Number
- NCT03637764
- Locations
- 🇺🇸
Investigational Site Number :8400007, Boston, Massachusetts, United States
🇺🇸Investigational Site Number :8400004, Santa Monica, California, United States
🇺🇸Investigational Site Number :8400002, Houston, Texas, United States